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Abstract. Odontogenic tumors and cysts, arising in the 
jawbones, grow by resorption and destruction of the jawbones. 
However, mechanisms underlying bone resorption by odonto-
genic tumors/cysts remain unclear. Odontogenic tumors/cysts 
comprise odontogenic epithelial cells and stromal fibroblasts, 
which originate from the developing tooth germ. It has been 
demonstrated that odontogenic epithelial cells of the devel-
oping tooth germ induce osteoclastogenesis to prevent the 
tooth germ from invading the developing bone to maintain 
its structure in developing bones. Thus, we hypothesized that 
odontogenic epithelial cells of odontogenic tumors/cysts induce 
osteoclast formation, which plays potential roles in tumor/
cyst outgrowth into the jawbone. The purpose of this study 
was to examine osteoclastogenesis by cytokines, focusing on 
transforming growth factor-β (TGF-β), produced by odonto-
genic epithelial cells. We observed two pathways for receptor 
activator of NF-κB ligand (RANKL) induction by keratocystic 
odontogenic tumor fluid: the cyclooxygenase-2 (COX-2)/
prostaglandin E2 (PGE2) pathway through interleukin-1α 
(IL-1α) signaling and non-COX-2/PGE2 pathway through 
TGF-β receptor signaling. TGF-β1 and IL-1α produced by 
odontogenic tumors/cysts induced osteoclastogenesis directly 
in the osteoclast precursor cells and indirectly via increased 
RANKL induction in the stroma.
Introduction
Recent research has indicated that the osteoclastogenesis 
induction factor, receptor activator of NF-κB ligand (RANKL), 
is involved in all bone resorption diseases regardless of inflam-
mation or tumor induction (1). RANKL, which is expressed in 
cells such as osteoblasts, promotes osteoclast differentiation 
through signals from receptors expressed by osteoclast precur-
sors (1,2). In addition, RANKL induces osteoclast formation 
and bone resorption at the disease site in rheumatoid arthritis 
through expression by synovial fibroblasts (3,4), tumor cells 
themselves (5) and lymphocytes (6). On the basis of the results 
of studies related to tooth germ development, cytokines and 
parathyroid hormone-related protein produced by the odonto-
genic epithelium promote osteoclast formation and protect the 
tooth germ from developing bone tissue by inducing RANKL 
expression in osteoblasts around the tooth germ and to be 
involved in the eruption of the tooth germ by regulating bone 
resorption (7,8).
Transforming growth factor-β (TGF-β) is a multifunctional 
cytokine that binds to its receptors on cell membranes, causes 
TGF-β receptor phosphorylation, and activates Smad2/3 to 
induce intracellular signal transmission (9). Interleukin-1α 
(IL-1α) is a multifunctional inflammatory cytokine (10). Both 
cytokines are expressed by the dental follicle (11). Furthermore, 
TGF-β, IL-1α, and tumor necrosis factor-α promote RANKL 
expression by the dental follicle, whereas the dental follicle 
is indicated to possess a latent ability to promote osteoclast 
formation (11-13). In addition, TGF-β directly promotes osteo-
clast differentiation of osteoclast precursors (14), and IL-1α 
also promotes osteoclast differentiation (15).
Typical neoplastic and cystic diseases of the jawbone 
include keratocystic odontogenic tumors (KCOTs), ameloblas-
tomas, and follicular cysts; these diseases originate in the tooth 
germ epithelial cells and enhance resorption of the surrounding 
jawbone. These lesions, in the process of developing within the 
jawbone, inevitably absorb or destroy the surrounding jawbone. 
Although cyst epithelial cell proliferation (16,17) and resorp-
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tion resulting from intracystic fluid-induced compression 
(18,19) have been widely accepted, the molecular regulation 
of this biological event is still unclear. With respect to the 
mechanism underlying this intracystic fluid-induced pressure, 
the mechanism underlying bone resorption in the primary 
lesion has not been explained, and there has been no examina-
tion of the activation or involvement of osteoclasts in the area 
surrounding the cysts and tumors. A previous study by Oka 
et al (20) reported that IL-1α produced by KCOTs promotes 
RANKL expression by stromal fibroblasts, suggesting the 
RANKL-mediating mechanism in the jawbones for tumors/
cysts expansion.
We therefore hypothesized that there is a potential cyto-
kine network that induces both RANKL expression and bone 
resorption in jawbone osteoclasts, thereby serving as a mecha-
nism for the growth of tumors and cysts.
Here we investigated the mechanism underlying RANKL 
expression in stromal fibroblasts to determine whether other 
cytokines produced by the odontogenic tumors and cell 
epithelium also affect this osteoclast formation and to suggest 
another mechanism underling tumors/cysts expansion in the 
jawbones.
Materials and methods
Cell culture and isolation of intracystic fluid. subjects were 
patients who underwent surgical removal of jaw tumors/cysts 
at the First department of Oral and maxillofacial surgery 
at Osaka University dental Hospital. After the appropriate 
explanation of the use of specimens and samples for research 
and obtaining consent, we harvested appropriately removed 
odontogenic tumors and cysts (KCOTs, ameloblastomas, and 
follicular cysts). We simultaneously performed fine-needle 
aspiration of intracystic fluid. Stromal fibroblasts were isolated 
and cultured with an explant method. For the experiment, we 
used stromal fibroblasts that had undergone 2-9 subcultures.
Intracystic fluid was aspirated using a fine needle and 
centrifuged at 740 x g at 4˚C for 10 min; the supernatant 
was then collected and centrifuged twice more at 13,400 x g 
at 4˚C for 10 min. This supernatant was then collected, 
sterilized using a filter with a pore size of 0.45 µm, and pre-
served at -80˚C until the experiment. For acid treatment of 
intracystic fluid, 12 M HCl was added (final concentration 
0.5 M HCl) to intracystic fluid, which was then incubated 
at 4˚C for 30 min. The acid was then neutralized with 10 M 
NaOH, at which point intracystic fluid was ready for use in 
the experiment.
Experiment reagents and antibodies. Recombinant human 
TGF-β1 (R&d systems, minneapolis, mN, UsA), recombinant 
human IL-1α (PeproTech, London, UK), and prostaglandin E2 
(PGE2; Cayman Chemical Co., Ann Arbor, mI, UsA) were 
used in the present experiment. The selective inhibitors used 
were an IL-1 receptor antagonist (IL-1Ra; PeproTech), TGF-β 
receptor inhibitor (sB-505124; sigma-Aldrich), and selective 
cyclooxygenase-2 (COX-2) inhibitor (CAY10404; Cayman 
Chemical Co.). The antibodies used were mouse monoclonal 
anti-TGF-β1,2,3 antibody (clone 1D11; R&D Systems), mouse 
monoclonal anti-human RANKL antibody (clone 70525.11; 
sigma-Aldrich), goat anti-human COX-2 antibody (Cayman 
Chemical Co.), and rabbit anti-phospho-Smad3 antibody 
(Rockland, Gilbertsville, PA, UsA).
Total RNA extraction and reverse transcription polymerase 
chain reaction. Stromal fibroblasts were seeded into a 6-well 
culture plate (Corning) and proliferated to confluency, at which 
point the culture medium was changed. Stromal fibroblasts 
were incubated with or without a sample or in the presence or 
absence of a reagent, and total RNA was extracted using a 
RNeasy mini kit (Qiagen, Hilden, Germany). In some experi-
ments, intracystic fluid was reacted at room temperature for 
1 h with mouse monoclonal anti-TGF-β1,2,3 antibody or 
stromal fibroblasts were pretreated at 37˚C for 1 h with 1 µM 
TGF-β receptor inhibitor, 50 ng/ml IL-1Ra, or 1 µM COX-2 
inhibitor; stromal fibroblasts were then incubated with or 
without a sample or in the presence or absence of a reagent, 
and total RNA was extracted. A total RNA template amount of 
0.8-1.5 µg was used. After incubating total RNA with ReverTra 
Ace reverse transcriptase (Toyobo, Osaka, Japan), random 
hexamer primer (Applied Biosystems, Foster City, CA, UsA), 
and RNase inhibitor (Promega, Madison, WI, USA) at 42˚C 
for 30 min, tRNA was then reacted at 99˚C for 5 min and at 
4˚C for 5 min to synthesize cDNA. The primers used were 
RANKL (sense, 5'-GGGTATGAGAACTTGGGATT-3'; and 
antisense, 5'-CACTATTAATGCCACCGAC-3'), osteoprote-
gerin (OPG) (sense, 5'-CCTGACCACTACTACACAGACA-3'; 
and antisense, 5'-GTTAGCAGGAGACCAAAGACACT 
GCA-3'), and glyceraldehyde-3-phosphate dehydrogenase 
(GAPDH) (sense, 5'-CCATCACCATCTTCCAGGAG-3'; and 
antisense, 5'-GCATGGACTGTGGTCATGAG-3'). PCR using 
the RANKL primer consisted of 35 cycles of heat treatment at 
94˚C for 9 min followed by thermal denaturation at 94˚C for 
1 min and annealing at 57˚C for 1 min; elongation was then 
performed at 72˚C for 10 min. PCR using the OPG and 
GAPDH primers consisted of 30 cycles of annealing at 59˚C 
for 1 min.
Total cellular protein extraction and western blotting. 
Stromal fibroblasts were seeded into a 60-mm cell culture dish 
(Corning) and proliferated to confluency. The culture medium 
was then changed to serum-free α-MEM with 0.3% bovine 
serum albumin, and stromal fibroblasts were cultured for 
16 h. Culture was subsequently performed in serum-free 
α-MEM with 0.3% BSA with or without a sample or reagent. 
Stromal fibroblasts were placed on ice for 20 min in RIPA lysis 
buffer (50 mM Tris-HCl, 150 mM NaCl, 1% Nonidet P-40, 
0.5% sodium deoxycholate, 0.1% SDS, pH 7.4; Santa Cruz 
Biotechnology, dallas, TX, UsA) containing protease and 
phosphatase inhibitor cocktails (both from sigma-Aldrich) 
and lysed. The cell lysate was then collected and centrifuged 
at 13,400 x g at 4˚C for 20 min; the supernatant was boiled 
in 5X sds sample buffer and used in the following experi-
ments. After performing electrophoresis on 20 µg of total 
cellular protein in a 10% SDS polyacrylamide gel, the gel was 
transferred to a PVdF membrane (Bio-Rad, Hercules, CA, 
USA). As primary antibodies, rabbit anti-phospho-Smad3 
(diluted 1:2,000) and goat anti-human COX-2 antibodies were 
diluted with T-PBS and reacted at 4˚C for 16 h. A lumines-
cence reaction was performed with an Amersham ECL Plus 
kit (GE Healthcare, Uppsala, sweden). Luminescent signals 
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were detected using a Kodak Gel Logic 2200 Imaging system 
(Carestream, Rochester, NY, UsA).
Immunohistochemical staining. Tissues from KCOTs and 
ameloblastomas were fixed in 10% formalin buffer solution 
and embedded in paraffin. Four-micrometer-thick paraffin 
sections were created, and deparaffinized sections were used 
in immunohistochemical staining. Immunohistochemical 
staining was performed with a Vectastain ABC kit (Vector 
Laboratories, Burlingame, CA, UsA) as per manufacturer's 
protocol. As primary antibodies, mouse monoclonal anti-
TGF-β1,2,3 (diluted 1:10), mouse monoclonal anti-human 
RANKL (diluted 1:50), rabbit anti-phospho-Smad3 (diluted 
1:500), and goat anti-human COX-2 antibodies (diluted 1:500) 
were diluted with blocking solution and reacted for 16 h at 4˚C.
Measurements of concentrations of TGF-β1 and IL-1α. 
Concentrations of TGF-β1 and IL-1α in KCOT, ameloblas-
toma, and follicular cyst intracellular fluid were determined 
using a human TGF-β1 ELIsA kit and IL-1α ELIsA kit 
(both from R&d systems) while simultaneously measuring 
absorbance at 450 nm with a microplate reader (model 680, 
Bio-Rad) in accordance with the manufacturer's instructions. 
Experimental results are presented as means ± standard 
deviation.
Measurement of concentration of prostaglandin E2. stromal 
fibroblasts were proliferated in a 24-well culture plate (Corning) 
to confluency. After washing these stromal fibroblasts twice 
with serum-free α-MEM culture medium containing 0.3% 
BsA, cells were cultured for 12 h in serum-free α-mEm 
culture medium containing 0.3% BSA. The culture medium 
was then changed, and cells were further incubated for 6 h with 
or without a sample or reagent in serum-free α-mEm culture 
medium containing 0.3% BSA. The culture supernatant was 
then collected and centrifuged at 13,400 x g at 4˚C for 10 min. 
The resulting supernatant was then collected and preserved at 
-80˚C until used in experiments. Concentrations of PGE2 in 
the culture supernatant were determined using a PGE2 ELIsA 
kit (Cayman Chemical Co.) while simultaneously measuring 
absorbance at 420 nm with the microplate reader, in accor-
dance with the manual. Experimental results are expressed as 
means ± standard deviation.
Statistical analyses. statistical analyses were performed using 
Student's t-test. P<0.05 was considered to be significant.
Results
Effects of KCOT fluid on RANKL and OPG expression in 
KCOT stromal fibroblasts. After KCOT stromal fibroblasts 
were cultured in the presence of KCOT fluid, reverse tran-
scription polymerase chain reaction (RT-PCR) was used to 
examine RANKL and OPG expression. It was found that 
RANKL expression was induced by KCOT fluid at 6 h and 
the expression peaked at 12 h. At 24 h, RANKL expression 
attenuated. There were no changes in OPG expression at any 
point in time. Next, acid treatment was performed to deter-
mine the physiochemical properties of intracystic fluid; it was 
found that RANKL expression was enhanced at 6, 12, 24 and 
48 h (Fig. 1).
Identical trends were observed in combinations of stromal 
fibroblasts and ameloblastoma fluid in three cases of amelo-
blastoma, stromal fibroblasts and follicular cyst fluid in two 
cases of follicular cysts, and stromal fibroblasts and KCOT 
fluid in three other cases of KCOT (data not shown). To ensure 
reproducibility in subsequent experiments, a large volume of 
intracystic fluid sample was collected, and the combination of 
KCOT stromal fibroblasts and KCOT fluid was chosen because 
of strong RANKL expression.
Effects of TGF-β1 and IL-1α on RANKL and OPG expression 
in KCOT stromal fibroblasts. The enhancement of physi-
ological activity resulting from acid treatment indicated the 
possible involvement of key cytokines, such as TGF-β, in this 
process, and we subsequently addressed this point in detail. 
We also examined the effect of IL-1α, another important 
factor present in odontogenic cysts that is known to induce 
RANKL expression.
After KCOT stromal fibroblasts were cultured in the pres-
ence or absence of TGF-β or IL-1α for 12 h, RT-PCR was used 
to examine RANKL and OPG expression. It was thus found 
that both TGF-β and IL-1α induced RANKL expression in 
a dose-dependent manner (Fig. 2A and B). In addition, when 
KCOT stromal fibroblasts were cultured in the combined 
presence of TGF-β1 and IL-1α for 12 h, induction of RANKL 
expression was further enhanced. OPG expression was not 
affected by culturing with TGF-β alone, IL-1α alone, or a 
combination of the two (Fig. 2C).
Involvement of TGF-β and IL-1 receptor signals in KCOT 
fluid-induced RANKL expression. To investigate whether 
TGF-β is substantially present in KCOT fluid, we examined 
Figure 1. Effects of acid treatment of KCOT fluid on RANKL and OPG expression in KCOT stromal fibroblasts. KCOT stromal fibroblasts were cultured in 
the presence of 1% KCOT fluid for the times displayed above, and RT-PCR was used to examine RANKL and OPG expression. Intracystic fluid was found to 
induce RANKL expression, whereas OPG demonstrated no changes. Acid treatment of KCOT fluid enhanced RANKL expression.
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Smad3 phosphorylation using western blotting. Consequently, 
Smad3 phosphorylation was observed 5 min after KCOT fluid 
stimulation; this phosphorylation was detected at 60 min as 
well (Fig. 3A). This result supports that TGF-β in KCOT fluid 
activated TGF-β receptor signals in KCOT stromal fibro-
blasts. To investigate whether TGF-β in KCOT fluid mediates 
RANKL expression in KCOT fibroblasts, RT-PCR was used 
to examine RANKL and OPG expression in KCOT stromal 
fibroblasts pretreated with anti-TGF-β antibody and cultured 
with KCOT fluid for 12 h. It was found that KCOT fluid-
induced RANKL expression was inhibited by anti-TGF-β 
antibody in a concentration-dependent manner (Fig. 3B). In 
addition, when KCOT stromal fibroblasts were pretreated with 
TGF-β receptor inhibitor and cultured for 12 h in the presence 
of KCOT fluid, RANKL expression was partially inhibited by 
TGF-β receptor inhibitor (Fig. 3B). Incomplete blockade of 
anti-TGF-β neutralizing antibody and TGF-β receptor inhib-
itor on KCOT fluid-induced RANKL expression suggests that 
another factor in intracystic fluid regulates RANKL expres-
sion; we therefore investigated the involvement of IL-1α.
Following pretreatment with the TGF-β receptor inhibitor, 
IL-1 receptor antagonist, or a combination of both, KCOT 
stromal fibroblasts were cultured in the presence of KCOT 
fluid for 12 h. RT-PCR was then used to examine RANKL and 
OPG expression.
It was found that induction of RANKL expression when 
stromal fibroblasts were cultured in the presence of TGF-β and 
IL-1α was roughly equal to that when they were cultured with 
KCOT fluid. RANKL expression induced by KCOT fluid was 
partially inhibited by the IL-1α receptor antagonist, strongly 
inhibited by TGF-β receptor inhibitor, and completely inhib-
ited by a combination of these two reagents (Fig. 4). These 
results suggest that TGF-β and IL-1α in KCOT fluid cooperate 
to induce RANKL expression in stromal fibroblasts.
Measurements of concentrations of TGF-β1 and IL-1α in 
odontogenic tumor and cyst fluid. Concentrations of TGF-β1 
and IL-1α in the odontogenic tumor and cyst fluid were 
measured using ELIsA. The mean concentration of TGF-β1 in 
KCOT fluid in 10 cases was 7820.6±8625.2 pg/ml, which was 
markedly high, whereas that of IL-1α was also markedly high 
at 3410.8±1592.8 pg/ml. The mean concentrations of TGF-β1 
and IL-1α in intracystic fluid in three cases of ameloblastoma 
were 606.8±264.5 and 387.3±654.0 pg/ml, respectively. Mean 
concentrations of TGF-β1 and IL-1α in intracystic fluid 
in the five cases of follicular cyst were 5142.2±5338.1 and 
Figure 2. Effects of TGF-β and IL-1α on RANKL and OPG expression in 
KCOT stromal fibroblasts. (A and B) KCOT stromal fibroblasts were cultured 
in the presence of TGF-β and IL-1α for 12 h, and RT-PCR was used to examine 
RANKL expression. Both TGF-β1 (A) and IL-1α (B) induced RANKL expres-
sion. OPG expression was unaffected. (C) Culturing in the presence of a 
combination of TGF-β and IL-1α for 12 h enhanced RANKL expression. OPG 
expression was unaffected.
Figure 3. Effects of phosphorylation of Smad3 in KCOT stromal fibroblasts, and effects of anti-TGF-β antibody and TGF-β receptor inhibitor on KCOT 
fluid-induced RANKL expression in KCOT stromal fibroblasts. (A) KCOT stromal fibroblasts were stimulated with 1% KCOT fluid, and phosphorylation of 
Smad3 was examined by western blotting. KCOT fluid stimulation was found to induce phosphorylation of Smad3. (B) KCOT stromal fibroblasts were 
cultured for 12 h in the presence of 1% KCOT fluid (with or without acid treatment as indicated by KCOT acid fluid) pretreated for 1 h with the above-displayed 
concentrations of anti-TGF-β antibody, and RT-PCR was used to examine RANK and OPG expression. KCOT stromal fibroblasts were also cultured for 12 h 
in the presence of KCOT fluid following 1 h of pretreatment with 1 µM of TGF-β receptor inhibitor, and RT-PCR was used to examine RANKL and OPG 
expression. Intracystic fluid-induced RANKL expression was inhibited by anti-TGF-β antibody in a concentration-dependent manner and by TGF-β receptor 
inhibitor.
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73.5±102.7 pg/ml, respectively; both of these concentrations 
were relatively low compared with those of KCOT (Fig. 5).
Investigation of localization of TGF-β, phosphorylated 
Smad3, RANKL, and COX-2 in KCOT and ameloblastoma 
tissues. Immunohistochemical staining was performed to 
examine whether induction of RANKL expression in stromal 
fibroblasts actually occurs within lesions via our model. 
staining for TGF-β in the KCOT tissue was strongly posi-
tive in the cyst epithelium, positive in lymphocytes that had 
infiltrated the interstitial tissue, positive in endothelial cells, 
and weakly positive in stromal fibroblasts. Staining for TGF-β 
in ameloblastoma was positive in tall columnar epithelial 
cells, weakly positive in asteroid cells, positive in endothelial 
cells, and weakly positive in stromal fibroblasts. Staining for 
phosphorylated Smad3 in KCOT was strongly positive in all 
layers of the cyst epithelium, particularly in basal cell nuclei, 
and was positive in stromal fibroblast nuclei. staining for 
phosphorylated Smad3 in ameloblastoma was positive in tall 
columnar epithelial cells, endothelial cells, and stromal fibro-
blasts (Fig. 6). staining for RANKL in the KCOT tissue was 
strongly positive in infiltrative lymphocytes, positive in the 
cyst epithelium, and positive in stromal fibroblasts. Staining 
for RANKL in ameloblastoma was weakly positive in epithe-
lial cells and stromal fibroblasts. Staining for COX-2 in the 
KCOT tissue was strongly positive in the cornified layer of 
the cyst epithelium and positive in stromal fibroblasts, infiltra-
tive lymphocytes, and endothelial cells. staining for COX-2 
in ameloblastoma was positive in epithelial cells, stromal 
fibroblasts, and endothelial cells (Fig. 7).
Mechanisms of COX-2 expression, PGE2 synthesis, and 
RANKL expression in KCOT stromal fibroblasts. Both TGF-β 
and IL-1α in intracystic fluid were shown to induce RANKL 
expression in stromal fibroblasts, whereas a combination of 
TGF-β and IL-1α was shown to strongly induce RANKL 
expression. The mechanism by which IL-1α induces RANKL 
expression is mediated by COX-2 and PGE2 synthesis (20,21). 
Therefore, we investigated whether TGF-β is also involved in 
these processes and whether this PGE synthesis promotes the 
induction of RANKL expression in stromal fibroblasts.
We examined the concentration of COX-2 protein resulting 
from culturing stromal fibroblasts for 6 and 12 h in the pres-
ence of KCOT fluid, TGF-β1, IL-1α, and a combination of 
TGF-β1 and IL-1α. It was found that although TGF-β1 did 
not increase COX-2 protein expression at 6 or 12 h, IL-1α 
did increase its expression. In addition, the combination of 
TGF-β1 and IL-1α synergistically increased COX-2 protein 
expression. Furthermore, KCOT fluid yielded an increase in 
COX-2 protein expression roughly equivalent to that yielded 
by a combination of TGF-β1 and IL-1α (Fig. 8A).
Next, we cultured KCOT stromal fibroblasts for 12 h in the 
presence of KCOT fluid following pretreatment with the TGF-β 
receptor inhibitor, IL-1 receptor antagonist, or a combination 
of both and then examined subsequent COX-2 expression. It 
was found that KCOT fluid-induced COX-2 protein expression 
Figure 4. Effects of TGF-β receptor inhibitor and IL-1 receptor antagonist 
on KCOT fluid-induced RANKL expression. The TGF-β receptor inhibitor 
(1 µM) and IL-1 receptor antagonist (50 ng/ml) were used to pretreat KCOT 
stromal fibroblasts for 1 h. These KCOT stromal fibroblasts were then 
cultured for 12 h in the combined presence of IL-1α (1 ng/ml) and TGF-β1 
(1 ng/ml) or 1% KCOT fluid (with or without acid treatment as indicated by 
KCOT acid fluid), and RT-PCR was used to examine RANKL expression. 
The increase in RANKL expression induced by the combination of TGF-β1 
and IL-1α was approximately equal to the increase induced by intracystic 
fluid. Intracystic fluid-induced RANKL expression was partially inhibited by 
the IL-1 receptor antagonist, strongly inhibited by TGF-β receptor inhibitor, 
and completely inhibited by a combination of the two.
Figure 5. Concentrations of TGF-β1 and IL-1α in odontogenic tumor and intracystic fluid. Concentrations of TGF-β1 (A) and IL-1α (B) in KCOT (◆), amelo-
blastoma (◼), and follicular cyst (▲) fluid were measured with ELISA. In KCOT, the mean concentrations of TGF-β1 and IL-1α were 7820.6±8625.2 and 
3410.8±1592.8 pg/ml, respectively (n=10). In ameloblastoma, the mean concentrations of TGF-β1 and IL-1α were 606.8±264.5 and 387.3±654.0 pg/ml, 
respectively (n=3). In follicular cyst, the mean concentrations of TGF-β1 and IL-1α were 5142.2±5338.1 and 73.5±102.7 pg/ml, respectively (n=5).
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Figure 6. Immunohistochemical staining for TGF-β and phosphorylated Smad3. Representative staining results for TGF-β (A and B) and phosphorylated 
Smad3 (C and D) in the KCOT (A and C) and ameloblastoma (B and D) are shown. The bar represents 50 µm.
Figure 7. Immunohistochemical staining for RANKL and COX-2. Representative staining results for RANKL (A and B) and COX-2 (C and d) in the KCOT 
(A and C) and ameloblastoma (B and D) are shown. The bar represents 50 µm.
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was not inhibited by TGF-β receptor inhibitor alone, but was 
nearly completely inhibited by the IL-1 receptor antagonist. 
The combination of TGF-β receptor inhibitor and IL-1α 
receptor antagonist did not inhibit COX-2 protein expression 
more than that by the IL-1α receptor antagonist alone (Fig. 8B).
After culturing stromal fibroblasts for 6 h in the presence 
of KCOT fluid, TGF-β1, IL-1α, and a combination of TGF-β1 
and IL-1α, we measured the concentration of PGE2 in the 
resulting supernatant. The mean concentration of PGE2 in 
untreated culture medium was 313.0±142.38 pg/ml. The mean 
concentrations of PGE2 in culture in the presence of TGF-β1, 
IL-1α, both TGF-β1 and IL-1α, KCOT fluid, ameloblastoma 
fluid, and follicular cyst fluid were 403.3±83.28, 2160.4±65.04, 
16046.2±264.87, 10970.8±405.21, 11683.2±602.28 and 
2393.7±43.71 pg/ml, respectively (~1.3, 6.9, 51.3, 35, 37.3 and 
Figure 8. Effects of KCOT fluid, TGF-β1, and IL-1α on COX-2 expression in KCOT stromal fibroblasts, and effects of TGF-β receptor inhibitor and IL-1 
receptor antagonist on KCOT fluid-induced COX-2 expression. (A) After culturing KCOT stromal fibroblasts for 6 or 12 h in the presence of TGF-β1 (1 ng/ml), 
IL-1α (1 ng/ml), and 1% KCOT fluid (with or without acid treatment as indicated by KCOT acid fluid), western blotting was performed to examine COX-2 
expression. Although TGF-β1 did not increase COX-2 protein expression, IL-1α did. The combination of TGF-β1 and IL-1α synergistically increased COX-2 
protein expression. KCOT fluid also increased COX-2 protein expression. (B) KCOT stromal fibroblasts were cultured for 12 h in the presence of 1% KCOT 
fluid following 1 h of pretreatment with the TGF-β receptor inhibitor (1 µM) and IL-1 receptor antagonist (50 ng/ml). Intracystic fluid-induced COX-2 
expression was not inhibited by TGF-β receptor inhibitor, but was nearly completely inhibited by the IL-1 receptor antagonist. The combination of TGF-β 
receptor inhibitor and IL-1α receptor antagonist did not inhibit COX-2 protein expression more than that inhibited by the IL-1α receptor antagonist alone.
Figure 9. Concentrations of PGE2 in KCOT stromal fibroblast culture super-
natant. Stromal fibroblasts were cultured for 6 h in the presence of TGF-β 
(1 ng/ml), IL-1α (1 ng/ml), and intracystic fluids; the concentration of PGE2 
in the resulting culture supernatant was then measured. Representative 
results are shown. The mean concentrations of PGE2 in culture medium were 
313.0±142.38 (untreated), 403.3±83.28 (TGF-β1-treated), 2,160.4±65.04 
(IL-1α-treated), 16,046.2±264.87 (TGF-β1 + IL-1α), 10,970.8±405.21 
(1% KCOT-treated), 1,1683.2±602.28 (2% ameloblastoma fluid-treated), and 
2,393.7±43.71 pg/ml (1% follicular cyst fluid-treated).
Figure 10. Effects of selective COX-2 inhibitor (CAY10404) on RANKL 
expression induced by TGF-β and KCOT fluid. Following 1-h pretreatment 
with the selective COX-2 inhibitor (1 µM), KCOT stromal fibroblasts were 
cultured for 12 h with TGF-β1 (1 ng/ml) and 1% KCOT fluid. RT-PCR was 
then used to examine RANKL expression. (A) TGF-β1-induced RANKL 
expression was only weakly inhibited by the selective COX-2 inhibitor. 
(B) Intracystic fluid-induced RANKL expression was strongly inhibited by 
the selective COX-2 inhibitor; recovery from this inhibition was achieved by 
culture in the presence of PGE2 (200 nm).
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7.6 times, respectively, higher than that yielded by untreated 
culture medium). While PGE2 concentrations in cultured 
samples of other intracystic fluids demonstrated widely varying 
increases from 1.4 to 537.6 times, these fluids displayed greatly 
increased concentrations of PGE2 (data not shown). In a mech-
anism consistent with the changes in COX-2 protein shown 
in Fig. 8A, TGF-β1 did not promote PGE2 synthesis, whereas 
IL-1α promoted PGE2 synthesis, and a combination of the two 
promoted PGE2 synthesis synergistically. In addition, PGE2 
synthesis was strongly promoted by jawbone tumor and cyst 
fluids (Fig. 9). Finally, we examined COX-2-mediated RANKL 
expression in stromal fibroblasts. Following pretreatment with 
a selective COX-2 inhibitor, KCOT stromal fibroblasts were 
cultured for 12 h in the presence of TGF-β1 or KCOT fluid; 
RT-PCR was then used to examine RANKL expression. It was 
found that RANKL expression induced by TGF-β1 was only 
weakly inhibited by the selective COX-2 inhibitor (Fig. 10A). 
Moreover, RANKL expression induced by KCOT fluid was 
strongly inhibited by the selective COX-2 inhibitor (Fig. 10B). 
In addition, recovery from this inhibition was achieved by 
culture in the presence of PGE2, a downstream target of 
COX-2 (Fig. 10B).
Discussion
Recent research has suggested that RANKL is involved in 
all bone resorption diseases regardless of inflammation or 
tumor induction (1). However, although cyst epithelial cell 
proliferation (16,17) and resorption resulting from intracystic 
fluid-induced compression (18,19) have long been proposed 
as mechanisms for the enlargement of maxillary tumors and 
cysts and have garnered widespread acceptance, no action 
has been taken on these proposals. Therefore, we determined 
whether the cytokines and stromal fibroblasts produced by 
odontogenic tumors and cysts are involved in osteoclast 
formation and to determine the molecular mechanism under-
lying this involvement. To address these points, we focused on 
the role of TGF-β and IL-1α, and we analyzed the mechanism 
underlying osteoclast formation. direct isolation of cytokines 
produced by odontogenic epithelial cells is technically diffi-
cult, and cytokines produced extracellularly were thought to 
be present in intracystic fluid. Therefore, by the stimulation 
of intracyctic cytokines, we investigated the regulation of 
RANKL expression, an osteoclast formation-inducing factor, 
in stromal fibroblasts.
In this study, KCOT fluid induced RANKL expression 
in stromal fibroblasts. This effect was enhanced on treating 
KCOT fluid with an acid (Fig. 1). Because TGF-β is known 
to be activated by acid treatment, we believed that TGF-β was 
present in KCOT fluid and was involved in RANKL expres-
sion. TGF-β1 induced RANKL expression in KCOT stromal 
fibroblasts in a concentration-dependent manner (Fig. 2A). 
RANKL expression was induced in a time-dependent manner 
from 3 to 12 h of culture and was attenuated beyond 24 h 
(data not shown). In TGF-β signal transduction, Smad2/3 is 
characteristically phosphorylated (9). Although KCOT fluid 
stimulation resulted in phosphorylation of Smad3 in KCOT 
stromal fibroblasts (Fig. 3A), phosphorylation of Smad2 was 
Figure 11. Mechanism underlying promotion of RANKL expression in KCOT stromal fibroblasts. It was demonstrated that TGF-β and IL-1α possess the latent 
capacity to directly promote osteoclast formation from osteoclast precursors and may be involved in jawbone resorption by inducing RANKL expression in 
stromal fibroblasts and promoting osteoclast formation. It was thus demonstrated that induction of RANKL expression in stromal fibroblasts occurs by two 
pathways: a TGF-β pathway, which is not mediated by COX-2-PGE2 synthesis, and an IL-1α pathway. It was also demonstrated that TGF-β signals synergisti-
cally promote IL-1α signal-induced COX-2-PGE2 synthesis, thus promoting RANKL expression.
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not detected with TGF-β stimulation (data not shown). Thus, 
the results in KCOT stromal fibroblasts suggested that TGF-β1 
activates Smad3 and exerts a biochemical effect. Treatment of 
KCOT fluid and KCOT stromal fibroblasts with anti-TGF-β 
antibody and TGF-β receptor inhibitor, respectively, inhibited 
the induction of RANKL expression (Fig. 3B). These results 
suggested that TGF-β is present in KCOT fluid and that TGF-β 
receptors activate Smad3 and induce RANKL expression in 
KCOT stromal fibroblasts.
The effects of TGF-β in relation to the regulation of 
RANKL and OPG expression in osteoblasts, as reported in 
previous studies, differ from the results obtained in stromal 
fibroblasts in this study as well as that obtained in a report on 
the effects of TGF-β in tooth germ fibroblasts (11). In particular, 
these past reports stated that TGF-β inhibited RANKL expres-
sion and promoted OPG expression (22,23). However, TGF-β 
increases RANKL expression in human osteoblasts isolated 
from clinical samples (24). Thus, it is possible that the mecha-
nism by which TGF-β regulates RANKL expression differs 
according to the type of cell and stage of cell differentiation. It 
is also possible that RANKL expression in odontogenic tumor 
and cyst stromal and tooth germ fibroblasts (11) is promoted 
by TGF-β.
KCOT f luid-induced RANKL expression was not 
completely inhibited by TGF-β antibody or TGF-β receptor 
inhibitor (Fig. 3B), but was completely inhibited by the 
IL-1 receptor antagonist (Fig. 4). This finding demonstrated 
that TGF-β1 and IL-1α in intracystic fluid induce RANKL 
expression in stromal fibroblasts. IL-1α promotes RANKL 
expression in KCOT stromal fibroblasts (20). In this study, 
IL-1α consistently induced RANKL expression in KCOT 
stromal fibroblasts (Fig. 2B), a result which is consistent with 
that observed in previous studies.
Both TGF-β1 and IL-1α were present in KCOT fluid in 
high concentrations. In addition, the concentrations of TGF-β1 
and IL-1α in ameloblastoma fluid, though lower than that 
in KCOT fluid, were nonetheless high. The concentration 
of TGF-β1 in follicular cyst fluid, though lower than that in 
KCOT fluid, was still high, and the concentration of IL-1α 
was low. The concentration of IL-1α in KCOT fluid is high, 
whereas the concentration of IL-6 in ameloblastoma fluid is 
high and shows disease specificity (25). In the results of this 
study as well KCOT fluid showed high concentrations of both 
TGF-β1 and IL-1α; this characteristic distinguishes KCOT 
from follicular cysts in which concentrations of IL-1α are low 
and suggests that TGF-β1 and IL-1α are disease specific and 
concentration of IL-1α could be used as a clinical marker to 
distinguish between these two lesions.
In immunohistochemical staining, KCOT and amelo-
blastoma epithelial cells were positive for TGF-β, which 
is consistent with the results of previous studies (26,27). 
Furthermore, immunohistochemical results for TGF-β and 
phosphorylated Smad3 demonstrated that TGF-β is produced 
by odontogenic epithelial cells and Smad3 is activated in the 
epithelial tissue and stromal fibroblasts, thus triggering intra-
cellular signal transduction. In addition, RANKL expression 
was confirmed in the KCOT and ameloblastoma interstitial 
tissue (Fig. 7A and B). Epithelial cells were also positive for 
RANKL. RANKL is expressed in vitro in ameloblastoma-
derived epithelial cells (28) and that ameloblastoma epithelial 
cells are positive for RANKL staining (29,30); however, the 
function of RANKL in ameloblastoma remains unknown and 
thus must be further investigated.
PGE2, which is synthesized by COX in the arachidonic 
acid cascade, is a biologically active substance that strongly 
promotes RANKL expression (31). In addition, COX exists 
both as COX-1 and COX-2. Although COX-1 is constantly 
expressed in cells and involved in the production of PGE2, 
which is necessary for physiological functions, COX-2 is 
expressed only when induced by stimuli, such as cytokines 
and growth factors, and is known to temporarily increase 
production of tissue-specific PGE2 (32). Therefore, regula-
tion of inducible COX-2 expression is important for synthesis 
of PGE2 by cellular stimulation. IL-1α promotes RANKL 
expression via synthesis of COX-2 and PGE2 (20,21).
This study determined that TGF-β and IL-1α induce 
RANKL expression in KCOT stromal fibroblasts. Based on 
this finding and on the fact that a combination of the above 
two factors enhanced induction of RANKL expression 
(Fig. 2C), we investigated the involvement of COX-2 and 
PGE2 in TGF-β-induced RANKL expression. We determined 
that although TGF-β1 did not promote synthesis of COX-2 
protein or PGE2 in stromal fibroblasts, it did synergistically 
promote IL-1α-induced synthesis of COX-2 protein and PGE2 
(Figs. 8 and 9). Also, although TGF-β1-induced RANKL 
expression was only weakly inhibited by a selective COX-2 
inhibitor, intracystic fluid-induced RANKL expression was 
strongly inhibited by the selective COX-2 inhibitor (Fig. 10). 
IL-1α-induced RANKL expression, which is mediated by 
COX-2/PGE2 synthesis, may have been inhibited and thus 
TGF-β1-induced RANKL expression was observed, which 
is not mediated by COX-2/PGE2 synthesis. The above find-
ings demonstrate that induction of RANKL expression in 
stromal fibroblasts occurs by two pathways: a TGF-β pathway, 
which is not mediated by COX-2/PGE2 synthesis, and an 
IL-1α pathway. It was also demonstrated that TGF-β signals 
synergistically promote IL-1α signal-induced COX-2/PGE2 
synthesis, thus promoting RANKL expression.
In addition, TGF-β and IL-1α act directly on osteoclast 
precursors and promote osteoclast differentiation (14,15). 
TGF-β promoted RANKL-dependent osteoclast differentia-
tion of human peripheral blood mononuclear cells and murine 
macrophage-like cell line RAW264, which are osteoclast 
precursors, and IL-1α also promoted osteoclast differentiation 
of the murine macrophage-like cell line RAW264 (data not 
shown).
The experiments described above demonstrated that 
TGF-β and IL-1α, cytokines which are produced by KCOT, 
ameloblastoma, and follicular cyst epithelial cells, possess the 
latent capacity to directly promote osteoclast formation from 
osteoclast precursors and may be involved in jawbone resorp-
tion by inducing RANKL expression in stromal fibroblasts and 
promoting osteoclast formation (Fig. 11). Previously reported 
mechanisms of growth of jawbone tumors, growth of cysts in 
the jawbone, and bone resorption include proliferation of cyst 
epithelial cells (16,17) and intracystic fluid-induced compres-
sive resorption (18,19). The results of this study demonstrate 
the involvement of another mechanism in which TGF-β1 and 
IL-1α produced by the jawbone tumor and cyst epithelial cells 
induce RANKL expression in stromal fibroblasts and promote 
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osteoclast formation. We believe that these findings will help 
in elucidating the mechanism underlying bone resorption in 
primary lesions.
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